Antibiotics available over the UK counter could be a dangerous trend

In 2005, and quietly, chloramphenicol eye drops started to become available for sale by pharmacists and without a doctor’s prescription. This was heralded at the time as a great advance for patients, who could get treatment for conjunctivitis faster, and for pharmacists, who could be more autonomous.

What is far less clear is whether or not this is actually good for patients. In the same year as the drops were made available, several pieces of research came out questioning whether or not they did much good: they seemed to shorten the time of infection slightly, but overall the usefulness of them as a routine treatment was rightly questioned.

What conclusions can we now draw? A study, by the Department of Primary Health Care at Oxford University reports in this month’s British Journal of General Practice.

In 2004 there were 2.3m prescriptions of chloramphenicol and this fell to 1.9 million in 2007. However, there has been a year-on-year increase in chloramphenicol sales in pharmacies, with a net increase of 47.8 per cent overall – 1.1m extra packs in annual use.

Is this a reflection of more and better treatment for eye infections? I don’t think so: I think it represents over-treatment. I am not aware of any research saying that eye infections weren’t being treated quickly enough pre 2005. I am aware, though, of lots of data everywhere telling us about antibiotic resistance and the problems of treating infection that wasn’t going to respond – because it was viral or because the drugs were inappropriate. And then we have “superbugs”, emerging as we use too much antibiotic…. And then there is the aspect of the pharmacy as a setting for this type of diagnosis.

I suspect the whole antibiotic over the counter thing has its roots in politics, not evidence. The next thing up for pharmacy distribution are antibiotics for urine infections.

Call me old fashioned, but I think that doctors are better able to prescribe antibiotics appropriately for all kinds of reasons. I fear disaster if this trend for more and more antibiotic use continues.

Health and science blog




This blog, part of the FT's health series, is a forum for readers interested in the science, policy, management, technology, business and delivery of healthcare.

This blog is no longer active but it remains open as an archive.
Follow on twitter

About our regular bloggers

Margaret McCartney is a Glasgow-based GP and FT Weekend columnist. She started writing for the Life and Arts section in 2005 and moved to the magazine in 2008. She also has her own blog: www.margaretmccartney.com/blog

Clive Cookson has been a science journalist for the whole of his working life. He joined the FT in 1987. Clive, the FT's science editor, picks out the research that everyone should know about. He also discusses key policy issues, from R&D funding to science education.

Andrew Jack is pharmaceuticals correspondent, covering the industry and public health issues. He has been a journalist with the FT for 19 years, based in London, Paris and Moscow

The Health blog: a guide

Comment: To comment, please register with FT.com, which you can do for free here. Please also read our comments policy here.
Contact: You can write to Ursula Milton, the blog's editor, using this email format: firstname.surname@ft.com
Time: UK time is shown on posts.
Follow: Links to the blog's Twitter and RSS feeds are at the top of the page. You can also read the Health blog on your mobile device, by going to www.ft.com/healthblog
FT blogs: See the full range of the FT's blogs here.